QOP
IMVT icon

Quinn Opportunity Partners’s Immunovant IMVT Stock Holding History

Quinn Opportunity Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501K Sell
13,000
-24,500
-65% -$746K 0.02% 273
2026
Q1 		$932K Sell
37,500
-23,608
-39% -$611K 0.05% 218
2025
Q4 		$1.55M Hold
61,108
– – 0.07% 190
2025
Q3 		$985K Buy
61,108
+10,000
+20% +$162K 0.07% 186
2025
Q2 		$818K Buy
51,108
+16,008
+46% +$242K 0.07% 205
2025
Q1 		$600K Buy
+35,100
New +$734K 0.04% 256

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quinn Opportunity Partners's IMVT Position: Q2 2026 in Review

Quinn Opportunity Partners reduced its Immunovant (IMVT) stake by 65% in Q2 2026, selling an estimated $746K and leaving 13,000 shares worth $501K. The position accounts for 0.02% of the portfolio, ranked #273.

Quinn Opportunity Partners first reported a position in IMVT in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.55M in Q4 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Quinn Opportunity Partners held 13,000 shares of Immunovant worth $501K as of Q2 2026.
  • Quinn Opportunity Partners sold 24,500 Immunovant shares in Q2 2026, an estimated $746K.
  • Immunovant made up 0.02% of Quinn Opportunity Partners's portfolio in Q2 2026, its #273 holding.
  • Quinn Opportunity Partners first reported a position in Immunovant in Q1 2025 and has held it in 6 quarters since.
  • Quinn Opportunity Partners's Immunovant position peaked at $1.55M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.